<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Ciprofloxacin - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Ciprofloxacin</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Antibiotics / Antivirals</div>
      <h1>Ciprofloxacin</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Ciprofloxacin 500mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Urinary tract infections (uncomplicated cystitis)</strong>
            <ul>
              <li>250 mg PO every 12 hours for 3 days (women; uncomplicated)</li>
              <li>Or 500 mg PO every 12 hours for 7 days if complicated or male patient</li>
            </ul>
          </li>
          <li><strong>Pyelonephritis (acute; when oral appropriate)</strong>
            <ul>
              <li>500 mg PO every 12 hours for 7 days (or longer based on severity/response; follow local guidelines)</li>
            </ul>
          </li>
          <li><strong>Infectious diarrhea (traveler's diarrhea / bacterial gastroenteritis when indicated)</strong>
            <ul>
              <li>500 mg PO every 12 hours for 1–3 days (duration depends on pathogen/severity)</li>
              <li>Note: increasing fluoroquinolone resistance in many regions; follow local guidelines</li>
            </ul>
          </li>
          <li><strong>Skin/soft tissue infections (when fluoroquinolone appropriate and organism susceptible)</strong>
            <ul>
              <li>500 mg PO every 12 hours for 7–14 days depending on severity</li>
            </ul>
          </li>
          <li><strong>Respiratory tract infections (selected cases; when appropriate pathogen coverage)</strong>
            <ul>
              <li>500 mg PO every 12 hours; duration varies by indication (typically 7–14 days)</li>
              <li>Note: not first-line for most CAP; reserve for specific indications/resistance patterns</li>
            </ul>
          </li>
          <li><strong>Bone/joint infections (when oral fluoroquinolone appropriate)</strong>
            <ul>
              <li>500 mg PO every 12 hours; prolonged course often needed (4–6 weeks or longer; follow specialist guidance)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Urinary tract infections (cystitis, pyelonephritis; when susceptible organisms and appropriate for resistance patterns)</li>
          <li>Infectious diarrhea (traveler's diarrhea, bacterial gastroenteritis when antibiotics indicated)</li>
          <li>Skin and soft tissue infections (when appropriate organism and resistance profile)</li>
          <li>Bone and joint infections (often combined with other agents; specialist guidance)</li>
          <li>Selected respiratory tract infections (not first-line for CAP in most settings)</li>
          <li>Intra-abdominal infections (often combined with metronidazole for anaerobic coverage)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to ciprofloxacin or other fluoroquinolones</li>
          <li><strong>Black box warnings (FDA/Health Canada):</strong>
            <ul>
              <li>Tendinitis and tendon rupture risk (especially Achilles tendon; increased risk in &gt;60 years, corticosteroid use, kidney/heart/lung transplant recipients)</li>
              <li>Peripheral neuropathy (can be irreversible)</li>
              <li>CNS effects (seizures, increased intracranial pressure, psychosis; caution in CNS disorders/epilepsy)</li>
              <li>Myasthenia gravis exacerbation (avoid use if possible)</li>
              <li>Serious adverse reactions: may outweigh benefits in uncomplicated infections (sinusitis, bronchitis, UTI) where other options exist</li>
            </ul>
          </li>
          <li>QT prolongation risk: caution with other QT-prolonging drugs, electrolyte abnormalities, or cardiac disease</li>
          <li>Pregnancy/lactation: avoid unless no alternative; potential for arthropathy in developing cartilage</li>
          <li>Renal impairment: dose adjustment required when CrCl &lt;30 mL/min</li>
          <li>Photosensitivity: advise sun protection during therapy</li>
          <li>C. difficile-associated diarrhea risk</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>GI upset (nausea, diarrhea, abdominal pain)</li>
          <li>CNS effects (headache, dizziness, insomnia; rarely seizures, confusion, psychosis)</li>
          <li>Tendinitis/tendon rupture (especially Achilles)</li>
          <li>Peripheral neuropathy (potentially irreversible)</li>
          <li>QT prolongation, arrhythmias (rare)</li>
          <li>Photosensitivity reactions</li>
          <li>Hypersensitivity reactions (rash; rarely severe)</li>
          <li>C. difficile-associated diarrhea</li>
          <li>Elevated liver enzymes</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>May take with or without food; taking with food may reduce GI upset</li>
          <li>Maintain adequate hydration during therapy</li>
          <li>Avoid dairy products, calcium, iron, zinc, antacids, and multivitamins within 2 hours before or 6 hours after dose (significantly reduce absorption)</li>
          <li>Counsel: finish prescribed course; report tendon pain, weakness, numbness/tingling, or CNS symptoms immediately</li>
          <li>Advise sun protection (photosensitivity risk)</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response to infection (symptoms, fever)</li>
          <li>Tendon pain or inflammation (Achilles, shoulder, hand); STOP if tendinitis suspected</li>
          <li>Neurologic symptoms (peripheral neuropathy, CNS effects); STOP if severe or concerning</li>
          <li>QT interval if high-risk patient or concurrent QT-prolonging drugs (when ECG available)</li>
          <li>Renal function if prolonged course or renal impairment</li>
          <li>Diarrhea (C. difficile consideration)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Reserve for appropriate indications where benefits outweigh significant risks; avoid as first-line for simple infections when alternatives exist</li>
          <li>Key maritime use: UTI/pyelonephritis, infectious diarrhea (traveler's diarrhea), selected resistant infections when other options not available</li>
          <li>Black box warnings are significant: counsel patients clearly about tendon rupture, neuropathy, and CNS risks</li>
          <li>If patient develops tendon pain or neurologic symptoms, STOP drug and reassess (do not continue)</li>
          <li>Document indication clearly; ensure appropriate stewardship (fluoroquinolone resistance is increasing globally)</li>
          <li>Avoid in older adults when safer alternatives exist (higher risk of serious adverse effects)</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (ciprofloxacin tablets): <a href="https://pdf.hres.ca/dpd_pm/00070195.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00070195.PDF</a></li>
          <li>FDA Safety Communication - Fluoroquinolone warnings: <a href="https://www.fda.gov/drugs/information-drug-class/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics" target="_blank" rel="noopener">https://www.fda.gov/drugs/information-drug-class/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics</a></li>
          <li>Medscape - Ciprofloxacin reference: <a href="https://reference.medscape.com/drug/cipro-ciprofloxacin-342502" target="_blank" rel="noopener">https://reference.medscape.com/drug/cipro-ciprofloxacin-342502</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
